



## ASX ANNOUNCEMENT

7 February 2025

# Opyl Announces Partnership with Avion

**Melbourne, Australia – Opyl Limited (ASX: OPL)**, a leader in clinical trial design and AI-powered biostatistical validation, is pleased to announce the signing of a service level agreement with Avion, a leading full-service Contract Research Organisation (CRO) dedicated to delivering end-to-end clinical trial solutions.

This strategic collaboration further validates Opyl's growing recognition and positive reception in the APAC region, as it follows successful partnerships with several well-known and highly respected CROs.

This upward trajectory demonstrates strong market validation of Opyl's proprietary TrialKey platform and its value in transforming clinical trial design, execution, and success rates.

### Key Highlights:

- **Strategic Collaboration:** The partnership combines Avion's expertise in clinical trial management with Opyl's proprietary TrialKey platform, delivering data-driven insights to optimise trial design and improve outcomes.
- **Market Validation:** Following partnerships with leading CROs in APAC, this agreement highlights growing recognition of Opyl's innovative solutions, reinforcing the platform's use case and validating its model in the clinical trial ecosystem.
- **Comprehensive Support:** Opyl will provide trial feasibility assessments, predictive analytics, and competitor benchmarking to complement Avion's operational excellence.

### Scope of Partnership

Under this agreement, Opyl and Avion will integrate the **TrialKey platform** into clinical trial planning and execution to achieve:

- Optimised trial design with AI-powered analytics.
- Improved site selection and participant recruitment strategies.
- Comprehensive, actionable reporting for enhanced decision-making.

For personal use only



The agreement will continue until terminated with 30 days' written notice. During this period, Opyl will provide Avion with detailed reports and actionable insights for \$5,000 AUD per report. Both parties have committed to working collaboratively to ensure seamless integration of the TrialKey platform into Avion's operations.

There are no material conditions that need to be satisfied before Avion adopts our TrialKey platform, there is no minimum number of reports commissioned under the agreement with Avion and there is no other material information relevant to assessing the impact of the agreement with Avion on the price or value of the Company's securities.

### **Executive Commentary**

**Damon Rasheed, Chief Technology Officer**, said:

*"This partnership is a testament to the growing demand for TrialKey across the APAC region and beyond. Our continued collaborations with respected CROs, like Avion, demonstrate the industry's confidence in our platform and its potential to transform clinical trials. Together, we're driving a shift toward data-driven strategies that deliver faster, more efficient, and higher-quality trial outcomes."*

**Dr Sam Vohra, Founder & CEO of Avion**, commented:

*"We are thrilled to partner with Opyl and integrate the TrialKey platform into our operations. This collaboration sets a benchmark for leveraging technology to optimise clinical trial strategies and achieve better outcomes for sponsors, patients, and the wider healthcare ecosystem."*

### **About Avion:**

Avion is a leading full-service CRO specialising in clinical trial execution and advanced imaging technologies. With expertise across oncology, dermatology, radiopharmaceuticals, and more, Avion delivers end-to-end trial services, seamlessly integrating imaging and data management to provide clients with superior results.

**This announcement has been authorised for release by the board**

**-ENDS-**



**For investor enquiries:**

Bernice Averion  
Head of Marketing and Communications  
Phone: +61 415 311 957  
Email: [bernice@trialkey.ai](mailto:bernice@trialkey.ai)

**About Opyl Limited (ASX: OPL)**

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.